A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma

Diseases and Conditions Researched

Bladder; Cancer

What is the purpose of this trial?

  • To evaluate the overall survival following administration of DN24-02
  • To evaluate disease free survival following administration of DN24-02
  • To evaluate the safety of DN24-02
  • To evaluate the magnitude immune response induced by administration of DN24-02
  • To evaluate the magnitude of cumulative CD54 upregulation following administration of DN24-02

Participation Guidelines

Age: Any
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Dendreon Corporation
Dates:
Last Updated:
Study HIC#: 1301011399